SequelSEC

BIOADAPTIVES, INC. BDPT

Pharmaceutical Preparations · CIK 0001575142 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$18.28K
Fiscal year ended 2025-12-31
Operating income
-$1.04M
Fiscal year ended 2025-12-31
Free cash flow
-$534.02K
Fiscal year ended 2025-12-31

BIOADAPTIVES, INC. (BDPT) reported revenue of $18.28K and net income of -$1.56M for the fiscal year ended 2025-12-31. This page shows 7 annual periods of income statement, balance sheet and cash flow figures normalized from BIOADAPTIVES, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

BIOADAPTIVES, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Revenue$18.28K$12.67K$28.56K$17.18K$19.78K$16.33K$9.93K
Cost of revenue$5.78K$8.64K$17.75K$10.05K$9.67K$10.23K$5.05K
Gross profit$12.50K$4.03K$10.82K$7.13K$10.10K$6.10K$4.88K
Operating income-$1.04M-$602.09K-$228.92K-$421.90KUnavailableUnavailableUnavailable
Net income-$1.56M-$899.16K-$712.47K-$895.57K-$1.05M-$847.24K-$238.93K
Research & developmentUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Weighted-average diluted sharesshares 10.07Mshares 8.22MUnavailableUnavailableUnavailableUnavailableUnavailable
Pretax income-$1.56M-$899.16KUnavailableUnavailableUnavailable-$847.24K-$238.93K
Income tax expense$0$0Unavailable$0$0$0$0
Diluted EPS$-0.15$-0.11UnavailableUnavailableUnavailableUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$820.51K$335.31K$101.48K$254.12K$268.27K$72.41K$88.93K
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

BIOADAPTIVES, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Cash & equivalents$215.20K$261.88K$88.56K$82.94K$82.94K$4.59K$12.31K
Total assets$225.90K$261.88K$104.00K$37.31K$148.58K$18.85K$24.21K
Current assets$211.90K$261.88K$88.56K$34.32K$88.88K$18.85K$24.21K
Total liabilities$2.36M$1.73M$1.75M$1.49M$1.24M$1.40M$864.09K
Current liabilities$2.36M$1.73M$1.75M$1.49M$1.24M$1.40M$864.09K
Total equity incl. NCI-$2.13M-$1.46M-$1.65M-$1.45M-$1.09M-$1.38M-$839.88K
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$44.71K$19.12K$15.28K$8.88K$4.75K$13.82K$11.13K
Accounts receivableUnavailable$0UnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payableUnavailableUnavailableUnavailable$0$1.75KUnavailableUnavailable

Cash flow

BIOADAPTIVES, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Operating cash flow-$516.02K-$249.52K-$223.77K-$227.26K-$158.65K-$106.89K-$168.12K
Capital expenditures$18.00K$0UnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flow-$18.00K$0UnavailableUnavailableUnavailableUnavailableUnavailable
Financing cash flow$555.00K$326.21K$259.14K$169.73K$237.00K$99.16K$124.22K
Net change in cashUnavailableUnavailableUnavailable-$57.53K$78.35K-$7.73KUnavailable
Stock-based compensation$28.67KUnavailableUnavailable$0$163.90K$47.12K$0
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

BIOADAPTIVES, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Free cash flow-$534.02K-$249.52KUnavailableUnavailableUnavailableUnavailableUnavailable
Gross margin68.4%31.8%37.9%41.5%51.1%37.3%49.2%
Operating margin-5701.8%-4752.5%-801.4%-2456.3%UnavailableUnavailableUnavailable
FCF margin-2921.7%-1969.5%UnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenue156.9%UnavailableUnavailableUnavailable828.8%288.6%0.0%
Current ratio0.09x0.15x0.05x0.02x0.07x0.01x0.03x
Revenue YoY growth44.3%-55.6%66.3%-13.1%21.1%64.4%Unavailable
Net margin-8523.4%-7097.3%-2494.2%-5214.1%-5309.2%-5189.2%-2405.1%
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenue98.5%0.0%UnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open BDPT in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-19View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-04-14View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.